Transgene Sa · EURONEXT:TNG
Transgene Sa — BioSquare 2004, Basel
14 slides from Transgene Sa's conference presentation, Mar 11, 2004
Slide 1: Transgene – BioSquare 2004, Basel
transgene I m m u n o t h e r a p y t o f i g h t c a n c e r Transgene BioSquare 2004, Basel Michel HUBERT VP Business Development March 11, 2004
Slide 2: Corporate Overview
Corporate Overview Development-stage biopharmaceutical company focused on cancer Product candidates based on proprietary gene transfer technology GMP-compliant manufacturing facilities Listed on EuroNext Nouveau Marché (TRANSGENE) and Nasdaq (TRGNY) 2 transgene
Slide 3: Key Data
Key Data Headcount: 165 (30 PhD’s) Sites: Strasbourg (France) and Boston (USA) Shareholders: Mérieux Group (70.3%) (5.9%) Human Genome Sciences Free Float (2.2%) Areva (19.5%) (2.1%) French Muscular Dystrophy Association Financials: Market capitalization: € 84.97 M (02/13/04) Cash-on-hand: € 34.9 M
Slide 4: Our strengths
Our strengths Data support further developments of all four cancer product candidates Mastering of 3 vector families In-house manufacturing and controls of clinical lots Opportunities to extract value from our technology and manufacturing platforms Broad IP portfolio : over 200 US, EU and Japan pate
Slide 5: CANCER Portfolio
CANCER Portfolio Indication Preclinical Phase I Phase II Phase III Cancer vaccines MVA-MUC1-IL2 Lung, Kidney, Prostate cancers MVA-HPV-IL2 Cervical cancer, VIN, CIN Immunotherapy products Ad-IL2 Malignant Melanoma and other solid tumors Ad-IFNγ Cutaneous T Cell Lymphoma Gene-induced chemotherapy MVA
Slide 6: MVA-MUC1-IL2 Vaccine Strategy
MVA-MUC1-IL2 Vaccine Strategy A cancer specific immunotherapy approach to induce a MUC1 specific immune response Peptides Transgene Carbohydrates approach Glycopeptide epitopes 6 Tumor cell membrane transgene
Slide 7: Cancer Vaccine: MVA-MUC1-IL2
Cancer Vaccine: MVA-MUC1-IL2 Phase II – Interim results Lung Combination with chemotherapy Final results mid-2004 12 evaluable patients 5 PR (1stage IIIb; 4 stage IV) Response duration : 144 – 195 days Prostate Monotherapy / 2 dosing schedules Final results mid-2004 21 enrolled patients significant
Slide 8: MVA-HPV-IL2: Product Design
MVA-HPV-IL2: Product Design Cancer Vaccine ü Non-invasive treatment ü Subcutaneous administration Recombinant MVA (Modified Virus Ankara) ü non-replicative, highly immunogenic poxvirus Expressing early genes E6/E7 of HPV16 ü virtually all CxCa are related to HPV (more than half to HPV16) ü E6 & E7 a
Slide 9: Cancer Vaccine: MVA-HPV-IL2
Cancer Vaccine: MVA-HPV-IL2 Phase II – Interim results Cervical Monotherapy Final results Q2 2004 cancer Amendment combination chemotherapy 2 disease stabilizations; 2 PR with chemotherapy out of 5 evaluable patients CIN2-3 Vaccination prior to conization Final results Q2 2004 21 evaluable patients
Slide 10: Immunotherapy: Ad-IFNγ
Immunotherapy: Ad-IFNγ Phase I/II ü Cutaneous lymphoma 36 000 patients EU+US ü Study design Dose escalation 9 3 dose levels 3.10 tp → 3.1011 tp 3 patients / dose level ü Treatment plan Intra-tumoral administration Weekly injections (D1, D8, D15 and tumor evaluation week) Maximum 4 cycles of treatmen
Slide 11: Immunotherapy: Ad-IL2
Immunotherapy: Ad-Il2 Phase I/II ü Melanoma and other solid tumors ü Study design Dose escalation 8 5 dose levels 3.10 tp → 3.1011 tp 3 patients / dose level ü Treatment plan Intra-tumoral administration Every 3 weeks for the first 7 injections then every 6 weeks ü Results 26 patients included (17 m
Slide 12: Tumor-targeted chemotherapy: MVA-FCU1
Tumor-targeted chemotherapy: MVA-FCU1 Bystander effect A promising approach ü Deliver 20x higher concentrations of chemotherapeutic 5-FU in the tumor ü Avoid side-effects of 5-FU systemic administration 12 transgene
Slide 13: Business Development Objectives
Business Development Objectives Cancer Products Identify partners for the development of our clinical candidates Targets In-licensing of targets/technologies in the cancer field Technology Out-licensing Vectors and Homologous recombination Platforms Manufacturing Subcontracting agreements for the pr
Slide 14: Transgene, 11 rue de Molsheim, Strasbourg
Transgene 11 rue de Molsheim 67082 Strasbourg Cedex France Contact : hubert@transgene.fr Tel : +33-(0)3.88.27.91.12 Web Site : www.transgene.fr 14 transgene